Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
Soysal T, Eskazan AE, Serin I, Sadri S, Keskin D, Ozgur Yurttas N, Berk S, Erdogan Ozunal I, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Ozbek U, Aydin Y. Soysal T, et al. Among authors: berk s. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e377-e384. doi: 10.1016/j.clml.2019.03.028. Epub 2019 Apr 4. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31088736
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcioglu B, Demirel N, Aydin D, Aydinli F, Yokus O, Ozunal IE, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: berk s. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):804-811. doi: 10.1016/j.clml.2017.07.255. Epub 2017 Aug 4. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28847475
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Ongoren S, Eskazan AE, Suzan V, Savci S, Erdogan Ozunal I, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Erbilgin Y, Iseri SA, Ar MC, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Ongoren S, et al. Among authors: berk s. Hematology. 2018 May;23(4):212-220. doi: 10.1080/10245332.2017.1385193. Epub 2017 Oct 9. Hematology. 2018. PMID: 28990873 Free article. Review.
Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.
Öztürk E, Özbalak M, Berk S, Erdoğan I, Avşar E, Dolgun A, Çetiner M, Mandel NM, Yalnız FF, Elverdi T, Salihoğlu A, Eşkazan AE, Ar MC, Öngören Ş, Başlar Z, Aydın Y, Soysal T, Ferhanoğlu B. Öztürk E, et al. Among authors: berk s. Leuk Lymphoma. 2016 May;57(5):1211-4. doi: 10.3109/10428194.2015.1079319. Epub 2015 Oct 12. Leuk Lymphoma. 2016. PMID: 26294270 No abstract available.
274 results